at-home testing

The company is initially targeting the large employer market with its app-connected biometric monitoring tools.

This news comes just months after it closed its $25 million Series B round. 

The companies are reported to have agreed on a $9 million deal with milestones for Inui Health (formerly known as Scanadu).

The Cue Health Monitoring System can deliver its results through a smartphone dashboard, and is intended for use by health professionals and consumers alike.

The startup, which specializes in a range of at-home testing kits, so far only offers a COVID-19 testing product for point-of-care providers.

Using a designated kit ordered by a doctor, patients will be able to self-swab and mail their samples to LabCorp testing facilities. The self-collection kits will be available in "most states" in the coming weeks.

Also Cue Health scores $13 million from the department of Health and Human Services Biomedical Advanced Research and Development authority in order to fund its portable COVID-19 diagnostic test.

Nurx, Carbon Health and Everlywell have officially halted their mail-order testing-kit services. But at least one startup is still moving to secure an Emergency Use Authorization for its at-home rapid serology diagnostic.

[Since this article was published, the FDA has released an alert warning that it has not yet authorized any COVID-19 home testing kits]

The company, which is growing 100% year over year, has now brought in a total of $8.2 million in funding.